Costa Rica’s landmark HPV trials continue to provide long-term data on single-dose efficacy and durability.Initial findings show >80% protection against HPV 16/18 infections sustained 10+ years after one dose—comparable to three doses.The ongoing ESCUDDO trial (20,000 girls) is testing non-inferiority of one vs. two doses, with results expected to guide future global policy.Primavera and Prisma […]